Serif Biomedicines claims breakthrough in non-viral gene therapy demonstrated in monkeys

Serif Biomedicines, a startup launched by Flagship Pioneering last month, announced it believes it has overcome two key technical hurdles that have limited non-viral gene therapy.

The company says the breakthrough was demonstrated in monkey studies, showing that modified DNA can be delivered without using viral vectors, which are traditionally associated with safety and manufacturing challenges.

Details of the data and the specific methods remain limited, and the claim has yet to be validated by independent researchers or regulatory bodies.